Case ReportOpen Access

Glucagonoma Neuroendocrine Tumor with the Clue of Necrolytic Migratory Erythematous Rash: A Case Report

Volume 2 - Issue 1

**Seyyed-Mohsen Hosseininejad¹,Fateme-Sadat Hosseininejad², Alireza Norouzi³ and Masoud Khoshnia*³**

Author Information Open or Close
- ¹Medical Student, Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
- ²Environmental health engineering student, Student Research Committee, Shahrood University of Medical Sciences, Shahrood, Iran
- ³Gastroenterologist, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
*Corresponding author: Masoud Khoshnia, Gastroenterologist, Golestan Research Center of Gastroenterology and Herpetology, Golestan University of Medical Sciences, Gorgan, Iran, Sayyad-Shirazi Blvd, Sayyad-Shirazi Hospital, Gorgan, Golestan Province, Iran

Received: January 10, 2018; Published: January 22, 2018

DOI: 10.26717/BJSTR.2018.02.000681

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Background: Necrolytic migratory erythema (NME) is most commonly a paraneoplastic condition. It is the dermatologic manifestation classically associated with glucagonoma pancreatic neuroendocrine tumor. Glucagonoma syndrome has been defined by the constellation of secreting tumor associated with overproduction by the α-cells in the pancreatic islets of Langerhans, abnormally elevated blood level of glucagon, and skin findings of NME.

Objective: Although it is not common, all physicians must have it in mind and consult for further investigation not to miss out NME.

Methods and Results: We report a case of a middle-aged female seen in clinic with longstanding skin lesions suggestive of NME revealing glucagonoma. Complete resolution of the cutaneous and systemic features occurred after surgical removal of the tumor.

Conclusion: NME is often the first clinical finding of an occult neuroendocrine pancreatic neoplasia. Physicians, especially general practitioners and dermatologists, must be aware of this condition subsequently they can be the first physician to suspect it and allow multidisciplinary management, which impacts the prognostic value. Surgical removal is the first-line therapy if early diagnosis is done before liver metastases arise.

Keywords: Glucagonoma Syndrome; Necrolytic Migratory Erythema; Paraneoplastic; Glucagonoma Syndrome; Pancreatic Neuroendocrine Tumor